Safety of enzalutamide in patients with mCRPC with hepatic dysfunction / 中华泌尿外科杂志
Chinese Journal of Urology
; (12): 47-50, 2021.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-933148
Responsible library:
WPRO
ABSTRACT
In March 2019, a patient with advanced prostate cancer was diagnosed in Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, and the disease progressed to the stage of mCRPC after traditional endocrinotherapy. Serious adverse event occurred after 1 month of treatment with abiraterone, which result in drug withdrawal, and replaced therapy by enzalutamide, the effect was good.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Urology
Year:
2021
Document type:
Article